Skip to main content

Table 2 Baseline results

From: First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

Parameters

Pembrolizumab plus EP

EP

LYs

1.83

1.51

QALYs

1.07

0.89

Total cost $

130,692

17,067

ICER $/LY a

346,818

-

ICER $/QALY b

647,509

-

WTP $/QALY

150,000

-

  1. EP: Etoposide and Platinum; ICER: incremental cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted life-year; WTP: willingness-to-pay
  2. a Compared to EP ($/LY)
  3. b Compared to EP ($/QALY)